Latest Vaccination Stories

PALO ALTO, Calif., Jan. 15, 2013 /PRNewswire/ -- Pelesend Inc., developer of health management applications for consumers, schools and healthcare providers, announced the availability of its free BeImmunized iPhone mobile app on iTunes. Building on the success of the BeImmunized browser version, the new BeImmunized app enables parents to provide school administrators proof of required immunizations right from their iPhone, saving time and eliminating hassles and confusion. "Until...

Vaccine Safety Datalink study of 1.4 million children at Group Health, etc., in Pediatrics Children age 12 to 35 months who receive DTaP vaccine in their thigh muscle rather than their arm are around half as likely to be brought in for medical attention for an injection-site reaction. So says a new study of 1.4 million children at Group Health and seven other Vaccine Safety Datalink (VSD) centers across the country, e-published on January 14 in Pediatrics. "These local reactions are the...

WORCESTER, Mass. and TORONTO, Jan. 11, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today announced that Company management has scheduled an investor conference call for Thursday, January 31, 2013. The purpose of the call is to provide the Company's stockholders with a review of recent Company activity and management's go-forward plans. The discussion will include: the clinical and regulatory status of the AE37 breast cancer vaccine and business development...

SEATTLE, Jan. 9, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study, being conducted at Mayo Clinic, Rochester, MN will progress. The proprietary HER2/neu Class II antigens, discovered by Keith Knutson Ph.D. and...

BLUE BELL, Pa., Jan. 9, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) and its development partner VGX International, Inc. (KSE: 011000) will move Inovio's hepatitis C (HCV) DNA vaccine into a phase I/IIa clinical trial by the end of 2013. This advancement is based on outstanding results of a preclinical study which demonstrated for the first time that a multi-antigen SynCon® HCV vaccine can generate robust T-cell responses not only in the blood but, more...

Despite the decline in cancer death rates in the U.S., there is an increase in incidence rates for cancers associated with human papillomavirus (HPV) infection and more efforts are needed to increase HPV vaccination coverage levels to prevent the occurrence of these cancers in the future according to a study published January 7 in the Journal of the National Cancer Institute. The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer...

Alan McStravick for redOrbit.com - Your Universe Online It was just about 14 years ago that a study published in the prestigious English medical journal The Lancet unleashed a firestorm of paranoia that swept new and expecting parents. At the time, it appeared to researcher Andrew Wakefield and his colleagues that there was a connection between the child immunization program for measles, mumps and rubella (MMR) and the diagnosis of autism. Wakefield’s contention was that the MMR...

TUCSON, Ariz., Jan. 7, 2013 /PRNewswire-USNewswire/ -- Eight employees, including at least three veteran nurses, have been fired by Goshen Hospital, in Goshen, Indiana, for refusing the flu vaccine. A religious exemption is available, but was denied because these employees did not meet the criteria for religious protection established by the Equal Employment Opportunity Commission. "What gives the EEOC the authority to define what constitutes an acceptable religious belief?" asks...

QUEBEC CITY, Jan. 7, 2013 /PRNewswire/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded an Indefinite Delivery / Indefinite Quantity (ID/IQ) contract from the Defense Advanced Research Projects Agency (DARPA) based on Medicago having met all the technical requirement standards...

WASHINGTON and BLUE BELL, Pa., Jan. 7, 2013 /PRNewswire/ -- The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies. Researchers will test whether a novel vaccine approach that combines genetically engineered DNA with an innovative vaccine delivery technology called electroporation could induce an immune response in humans...